Myeloma Paper of the Day, September 18th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Transcriptional profiling on renal bxs from NEOD00 (RAIN) trial identifies 2 distinct groups of patients with AL amyloidosis based on molecular signatures with activation of fibrotic pathways and canonical LPS/IL-1 signaling.”

Source: Robert Orlowski/X

Gene Expression Sets and Renal Profiling from the Renal AL Amyloid Involvement and NEOD00 (RAIN) Trial

Authors: Cindy Varga, Felix Eichinger, Viji Nair, Abhijit S Naik, Samih H Nasr, Agnes B Fogo, Denis Toskic, Matthias Kretzler, Raymond L Comenzo.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.